Filing summary
Entity and period: The supplied filing is Galena Biopharma, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2012; it does not identify SELLAS Life Sciences Group, Inc. as the registrant. Galena described itself as a development-stage biopharmaceutical company focused on cancer immunotherapies.
Business and development context
Galena’s lead candidate, NeuVax, was in the Phase 3 PRESENT trial for early-stage breast cancer. The company also planned a NeuVax-plus-Herceptin Phase 2 trial and was advancing its FBP vaccine in a Phase 1/2 trial. Galena reported no revenue since inception and said product revenue might not arise in the foreseeable future, if ever.
Financial results and liquidity
Amounts below are in millions of dollars unless stated otherwise. Revenue and gross margin are not applicable because the company had no revenue.
| Metric | Q2 2012 / June 30, 2012 | Comparable period / prior balance |
|---|---|---|
| Net loss | $0.196 for three months; $24.957 for six months ended June 30 | $3.754 loss for Q2 2011; $7.599 loss for first half 2011 |
| Operating loss | $5.683 for Q2; $10.093 for first half | $2.278 for Q2 2011; $5.458 for first half 2011 |
| Research and development expense | $3.720 for Q2; $6.384 for first half | $0.329 for Q2 2011; $0.390 for first half 2011 |
| General and administrative expense | $1.963 for Q2; $3.709 for first half | $1.949 for Q2 2011; $5.068 for first half 2011 |
| Cash and cash equivalents | $19.228 | $11.433 at December 31, 2011 |
| Current assets / current liabilities | $20.089 / $9.322 | $11.810 / $11.202 at December 31, 2011 |
| Total liabilities | $19.843 | $20.856 at December 31, 2011 |
| Net cash used in operating activities | $11.630 for first half | $7.086 for first half 2011 |
| Net cash provided by financing activities | $19.512 for first half | $18.013 for first half 2011 |
Current-asset coverage improved; working capital was approximately $10.767 million at June 30, versus $0.608 million at year-end. The company reported no product sales or operating margins. Convertible notes payable were zero at June 30, compared with $0.500 million at year-end; capital lease obligations totaled $0.057 million. Current liabilities included $5.229 million of warrants potentially settleable in cash and $0.897 million of current contingent acquisition consideration.
Changes, unusual items, and management outlook
- First-half net loss increased by $17.358 million year over year, primarily reflecting $11.632 million of warrant-related expense from fair-value changes and settlements, higher NeuVax trial costs, and $1.548 million of expense from revaluing contingent acquisition consideration.
- Q2 net loss improved year over year, but results included $5.929 million of other income, primarily from a decrease in the fair value of warrant liabilities. These non-cash valuation effects make reported earnings volatile; Q2 continuing operations showed income of $0.227 million before the $0.423 million discontinued-operations loss.
- R&D expense rose sharply as the Phase 3 PRESENT trial ramped up. The RXi spin-off was completed April 27, 2012; RXi results are reported as discontinued operations. Galena retained RXi shares subject to a one-year lockup, but carried its investment at zero for accounting purposes.
- Management said existing cash should fund operations through at least the second quarter of 2013. It expected significant continuing losses and higher R&D spending, and said future operations would depend on financing, collaboration, or other funding. It cautioned that additional funding might not be available on acceptable terms or at all.
- A key clinical and supply risk was Genzyme’s June 2012 recall of liquid Leukine, the GM-CSF used with NeuVax. Galena began using lyophilized Leukine at U.S. trial sites and believed supply was adequate, but foreign-site regulatory approvals and continued sole-source supply could delay enrollment or trial milestones.
- Four warrant-holder lawsuits were settled in May 2012; plaintiffs agreed to dismiss their claims, and Galena reimbursed specified legal fees and costs. The filing reported no material subsequent events, while noting a July issuance of 200,000 shares for advisory services.
- The filing stated disclosure controls were effective and that no material change in internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Confirm the issuer and filing period: the provided document names Galena Biopharma, Inc., not SELLAS Life Sciences Group, Inc.
- Review cash burn and financing needs against management’s stated runway through at least Q2 2013, including the assumptions underlying that estimate.
- Track NeuVax PRESENT enrollment, Leukine supply and foreign regulatory approvals, and any effect on trial timing.
- Separate operating performance from warrant and contingent-consideration fair-value movements when assessing losses and future liabilities.
- Check dilution and potential share issuance: the filing reported 66.960 million common shares outstanding at June 30 and 17.524 million shares reserved for warrants, options, and plan availability.